Novartis next generation eye drug outperforms Eylea
June 20, 2017Brolucizumab could offer quarterly dosing schedule.
X
Novartis next generation eye drug outperforms Eylea
https://pharmaphorum.com/news/novartis-plans-filing-new-eye-drug/
ophthalmology
Novartis takes aim at Shire and Allergan with dry-eye drug
April 7, 2017Swiss company takes option on Lubris’ ECF843.
Shire looks to eye drug as sales beat forecasts
February 17, 2017Company reports better than expected full year figures.
Novartis to buy ophthalmology firm Encore Vision
December 20, 2016Swiss pharma buys treatment for common age-related vision problem.
Novartis/Ophthotech eye combo fails in phase 3
December 12, 2016Lucentis and pegpleranib combination misses goal in wet AMD.
Novartis could sell Alcon eyecare business
November 15, 2016Swiss pharma looks to offload struggling division.
Regeneron to develop long release Eylea successor
October 14, 2016Regeneron teams with Ocular Therapeutix to develop next-gen Eylea formulation
Shire launches potential blockbuster dry eye drug in US
August 30, 2016Xiidra could be ophthalmology blockbuster.
Allergan thinks small with eye implant acquisition
August 12, 2016Move will add to ophthalmology offering
1 2
